Strategic Partnerships Zevra Therapeutics collaborates with patient advocacy groups, physicians, and care partners in clinical and regulatory development, signaling openness to external collaborations. This creates a strong pathway for partnering with diagnostics, genetic testing, and companion therapy initiatives to expand reach for rare disease programs.

Leadership & Talent With a recent CFO appointment and a high-profile Chief Medical Officer transition, Zevra is navigating growth and financial discipline. This presents opportunities to offer valuation services, strategic advisory, investor relations support, and executive search or interim leadership solutions during leadership changes.

Investor Outreach Active participation in investor conferences and public disclosures indicates ongoing fundraising and stakeholder engagement. Sales opportunities exist for investor-focused services, market access narratives, and sponsor-ready data packages aligning with life sciences funds and strategic investors.

Genetic Testing Collaboration A partnership with GeneDx to launch sponsored genetic testing for Niemann-Pick disease Type C demonstrates interest in expanding diagnostic reach. There is potential to offer additional genetic screening programs, data analytics, and payer-friendly testing solutions to broaden patient identification and trial recruitment.

Commercialization Readiness As a commercial-stage company with a mid-size employee base and a late-stage pipeline, Zevra is positioned for market access and payer negotiations. Opportunities include real-world evidence generation, health economics outcomes research, and advisory services to optimize pricing, reimbursement, and launch readiness for rare-disease therapies.